^
Association details:
| Biomarker: | EZH2 underexpression |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer
Published date:
02/24/2022
Excerpt:
Eighty LARC patients...All ptients received concurrent chemotherapy and oral capecitabine...Relationship Between Expression of RUNX3 and EZH2 and Other Clinical Factors and Response to Neoadjuvant Chemoradiotherapy...Patients with high expression of RUNX3 were more sensitive to neoadjuvant chemoradiotherapy...patients with low expression of EZH2 were more sensitive to neoadjuvant chemoradiotherapy...
DOI:
10.3389/fonc.2022.713335
